The results were are shown below.
(1) incidence of pneumococcal bacteremia per 100,000: 55.2 (best case-worst case, 55.4 - 42.9) for the age group 65-74 years; 88.5 (95.4 - 60.9) for 75-84 years; and 184.6 (235.6 - 120.2) for 85 years and over.
(2) mortality, 30 (43 - 15) for the age group 65-74 years; 26 (43 - 15) for 75-84 years, and 35 (43 - 29) for 85 years and over.
(3) proportion of mortality caused by vaccine serotypes, 88 (93 - 84).
(4) anaphylaxis cases per million doses, 5.
(5) quality-adjusted life-year weights for different age groups: 0.76 for the age group 65-69 years; 0.74 for 70-74 years; 0.70 for 75-79 years; 0.63 for 80-84 years; and 0.51 for 85 years and over.
(6) quality-adjusted life-year weights for bacteremia cases, 0.21.
The effectiveness and duration of protection of pneumococcal vaccine against vaccine serotypes was plotted for the age categories of 65-74, 75-84, and 85 years and older. Mortality rates for all causes were projected from the 1992 data.